Keywords
autologous transplant, mortality, risk factors
How to Cite
Berro, M., Arbelbide, A., Rivas, M., Basquiera, A., Ferini, G., Vitriu, A., Foncuberta, C., Fernández Escobar, N., Requejo, A., Milovic, V., Yantorno, S., Szelagowsky, M., Martínez Rolon, J., Bentolila, G., García, J., García, P., Caeiro, G., Castro, M., Jaimovich, G., Palmer, S., Bullorsky, E., Saslavsky, M., Duarte, P., Cerutti, A., Jarchum, G., Rizzi, M., Trucco, J., Bet, L., Tisi Baña, F., & Kusminsky, G. (2019). Prediction of mortality risk in autologous hematopoietic transplantation. GATMO score. Journal of Hematology, 21(3), 274–280. Retrieved from https://mail.revistahematologia.com.ar/index.php/Revista/article/view/165
Abstract
-
References
1. Sureda A et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Biol Blood Marrow Transplant.
2015;50:1037-1056.
2. Majhail N et al. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American society for blood and marrow transplantation. Biol Blood Marrow
Transplant. 2015;21:1863-9.
3. Gratwohl A et al. Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;39:71-87.
4. Suciu S et al. Allogeneic compared to autologous stem cell transplantation in the treatment of patients younger than 46 years with acute
myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMA AML-10 trial. Blood. 2003;102:1232-1240.
5. Pivkova Veljanovska A et al. Assesment of no relapse mortality (NRM) and long term survival after autologous stem cell transplantation (ASCT) in patients with lymphoproliferative diseases.
Contrib Sec boil.Med.Sci. 2012;33(1):107-19.
6. Saad A et al. Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2014;20:402-408.
7. Brockelmann P et al. Risk factors and a prognostic score for survival after autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma. Ann Oncol. 2017; doi: 10.1093/
annonc/mdx072. [ahead of print].
8. Satwani P et al. A prognostic model predicting autologous transplantation outcomes in children, adolescent and young adults with Hodgkin lymphoma. Bone Marrow Transplant. 2015;50:1416-1423.
9. Khouri I et al. Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of β2-microglobulin and
tumor score. Cancer. 2003;98:2630-5.
10. Sorror ML et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912-2919.
11. Sorror M et al. Prospective validation of the predictive power of the Hematopoietic Cell Transplantation Comorbidiy Index: a Center for the Internation Blood and Marrow Transplant Research Study. Biol Blood Marrow Transplant. 2015;21:1470-1487.
12. Jaglowski S et al. The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT.CI) can predict for 30-day readmission following autologous stem cell transplant for lymphoma and
multiple myeloma. Biol Blood Marrow Transplant. 2014;49(10):1323-1329.
13. Berro M et al. Hematopoietic Cell Transplantation-Specific Comorbiditiy Index predicts morbidity and mortality in autologous stem cell transplantation. Biol Blood Marrow Transplant.
2017;23:1646-1650.
14. Jantunen E et al. Autologous stem cell transplantation in elderly patients (≥ 60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry. Haematologica. 2008;93(12):1837-1942.
15. Bitran J et al. Hidgh-dose myeloablative therapy and autologous peripheral blood progenitor cell transplantation for elderly patients (greater than 65 years of age) with relapsed large cell lymphoma. Biol Blood Marrow Transplant. 2003;9:383-388.
16. Chihara D et al. High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed/refractory diffuse large B cell lymphoma: a nationwide retrospective study. Biol Blood Marrow Transplant. 2014;20:684-689.
17. Ludwig H et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10549 patients from the International Myeloma Working Party. Blood. 2008;111:4039-47.
18. Alegre A et al. Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish registry. Bone Marrow Transplant. 1998;21:133-140.
19. Smeland K et al. A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma. Br J Haematol. 2016; 173:432-43.
20. Martinez C et al. Comorbidities, not age, are predictive of survival after autologous hematopoietic cell transplantation for relapsed/ refractory Hodgkin´s lymphoma in patients older than 50 years. Ann Hematol. 2017;96:9-16.
2015;50:1037-1056.
2. Majhail N et al. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American society for blood and marrow transplantation. Biol Blood Marrow
Transplant. 2015;21:1863-9.
3. Gratwohl A et al. Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;39:71-87.
4. Suciu S et al. Allogeneic compared to autologous stem cell transplantation in the treatment of patients younger than 46 years with acute
myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMA AML-10 trial. Blood. 2003;102:1232-1240.
5. Pivkova Veljanovska A et al. Assesment of no relapse mortality (NRM) and long term survival after autologous stem cell transplantation (ASCT) in patients with lymphoproliferative diseases.
Contrib Sec boil.Med.Sci. 2012;33(1):107-19.
6. Saad A et al. Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2014;20:402-408.
7. Brockelmann P et al. Risk factors and a prognostic score for survival after autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma. Ann Oncol. 2017; doi: 10.1093/
annonc/mdx072. [ahead of print].
8. Satwani P et al. A prognostic model predicting autologous transplantation outcomes in children, adolescent and young adults with Hodgkin lymphoma. Bone Marrow Transplant. 2015;50:1416-1423.
9. Khouri I et al. Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of β2-microglobulin and
tumor score. Cancer. 2003;98:2630-5.
10. Sorror ML et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912-2919.
11. Sorror M et al. Prospective validation of the predictive power of the Hematopoietic Cell Transplantation Comorbidiy Index: a Center for the Internation Blood and Marrow Transplant Research Study. Biol Blood Marrow Transplant. 2015;21:1470-1487.
12. Jaglowski S et al. The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT.CI) can predict for 30-day readmission following autologous stem cell transplant for lymphoma and
multiple myeloma. Biol Blood Marrow Transplant. 2014;49(10):1323-1329.
13. Berro M et al. Hematopoietic Cell Transplantation-Specific Comorbiditiy Index predicts morbidity and mortality in autologous stem cell transplantation. Biol Blood Marrow Transplant.
2017;23:1646-1650.
14. Jantunen E et al. Autologous stem cell transplantation in elderly patients (≥ 60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry. Haematologica. 2008;93(12):1837-1942.
15. Bitran J et al. Hidgh-dose myeloablative therapy and autologous peripheral blood progenitor cell transplantation for elderly patients (greater than 65 years of age) with relapsed large cell lymphoma. Biol Blood Marrow Transplant. 2003;9:383-388.
16. Chihara D et al. High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed/refractory diffuse large B cell lymphoma: a nationwide retrospective study. Biol Blood Marrow Transplant. 2014;20:684-689.
17. Ludwig H et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10549 patients from the International Myeloma Working Party. Blood. 2008;111:4039-47.
18. Alegre A et al. Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish registry. Bone Marrow Transplant. 1998;21:133-140.
19. Smeland K et al. A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma. Br J Haematol. 2016; 173:432-43.
20. Martinez C et al. Comorbidities, not age, are predictive of survival after autologous hematopoietic cell transplantation for relapsed/ refractory Hodgkin´s lymphoma in patients older than 50 years. Ann Hematol. 2017;96:9-16.
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar
Downloads
Download data is not yet available.